New defence against viral lung infections discovered

18th March 2021

A newly defined immune mechanism provides protection from viral lung infection by suppressing lung inflammation. This is likely to be important as a first defence against infection, especially influenza and SARS-CoV-2.

Researchers have uncovered a previously unknown arm of the immune defence system that protects the lung from lethal viral infections.

Respiratory diseases caused by viruses such as influenza A and SARS-CoV-2 cause damage not just through their own actions, but also from collateral damage as the immune system reacts to fight the infection.

A timely and proportionate response identifies viruses, isolating them in tiny vesicles called phagosomes that are then targeted for breakdown. This process also triggers production of cytokines to alert the immune system.

Cytokine responses represent a fine balancing act that can sometimes tip over to an excessive state known as the cytokine storm. This has serious consequences for viral lung infections, as it leads to inflammation, fluid building up in the lungs and eventually death.

Given the impact of respiratory conditions, brought into sharp focus by the COVID-19 pandemic, there’s a clear need to fully understand the complexities of this immune response to develop better treatments or targets for drugs that can protect against infections taking hold.

To address this teams from the Quadram Institute and universities of Liverpool, East Anglia (UEA), and Bristol have worked together to study the immune response to influenza A virus infection in the lungs of mice. Animal models provide a way of understanding how the immune system works, and as with SARS-CoV-2, animals may be a significant reservoir for viruses that, if transferred to humans, can trigger pandemics.

Funded by the Biotechnology and Biological Sciences Research Council, they focussed on a recently characterised form of non-canonical autophagy called LC3-associated phagocytosis (LAP) that recognises pathogens as they enter cells.

Professor Tom Wileman at the Quadram Institute has worked with Dr Penny Powell and Professor Ulrike Mayer at UEA to develop a LAP-deficient mouse to study viral infection. Unique to this study, the mice were designed to retain the normal autophagy machinery, and target LAP within immune cells, so are the best available option for understanding the precise role of this newly uncovered immune defence.

Prof James Stewart at the University of Liverpool characterised the function of LAP by infecting the transgenic mice with influenza virus and studying the response to infection.

The mice were found to be much more susceptible to the virus, with it triggering a cytokine storm leading to pneumonia. The researchers showed that LAP prevented a lethal cytokine storm by supressing lung inflammation.

So where does this protection come from? Dr Yohei Yamauchi and colleagues from the University of Bristol provided the answer by looking at the cells lining the surface of the lung. There was no difference in how the virus initially binds to these cells, but they did see that non-canonical autophagy/LAP did slow the way the virus enters the cell. It may work by preventing the virus fusing with endosomes, which are the cell’s way of importing materials from outside.

Non-canonical autophagy/LAP is likely to be important as a first defence against infection, where there is no immunity from previous infections, especially in the specific case of influenza and SARS-CoV-2.

“Being able to describe this novel part of the immune defence system against respiratory infections in very exciting, especially given the current pandemic” commented Professor Tom Wileman from the University of East Anglia and Quadram Institute.

“We need to assess whether the same system provides similar protection in humans, but this does point to the possibility of developing new drugs that manipulate this non‐canonical autophagy to increase resistance at the lung surface, where it is most needed.”

Reference: Non‐canonical autophagy functions of ATG16L1 in epithelial cells limit lethal infection by influenza A virus, Yingxue Wang, Parul Sharma, Matthew Jefferson, Weijiao Zhang, Ben Bone, Anja Kipar, David Bitto, Janine L Coombes, Timothy Pearson, Angela Man, Alex Zhekova, Yongping Bao, Ralph A Tripp, Simon R Carding, Yohei Yamauchi, Ulrike Mayer, Penny P Powell, James P Stewart, Thomas Wileman.

The EMBO Journal (2021)40:e105543 DOI: 10.15252/embj.2020105543

Related Targets

Coronavirus (COVID-19)

Related Research Groups

Tom Wileman

Related Research Areas